-
'We expect our North America business to gain momentum from FY26 onwards, supported by our growing respiratory and injectable portfolio,' says CMD Glenn Saldanha
-
The drug firm has so far commercialised the product in 31 geographies across the globe.
-
Shares of Natco, Glenmark and Aurobindo Pharma are up 14, 10 and 2 percent respectively in the session.
-
Developed by Pfizer, abrocitinib has received marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO), the companies said in a statement on Wednesday.
-
Pharma stocks surged nearly 10% on Friday taking Nifty Pharma index up 3%, with Glenmark Pharma seeing the largest rise of up to 9.5 percent. Here's what's fuelling the rally in Pharma stocks.
-
Saldhana added that the management of Glenmark Lifesciences will remain intact
-
Glenmark Pharmaceuticals has entered into an agreement with the DOJ to resolve all of its court proceedings involving historical pricing practices by former employees relating to the generic drug pravastatin between 2013 and 2015.
-
The Sensex was up 234 points at 61,963.68, and the Nifty was up 111 points at 18,314.40, as IT, pharma and metal stocks led the gains. About 1,721 shares advanced, 1,783 declined and 168 remained unchanged
-
Glenmark’s growing leverage is prompting the company to explore immediate measures, such as the stake sale
-
The Mumbai-based company reduced the price of FabiFlu to 75 rupees ($1.00) per tablet last week for restricted emergency use in patients with mild-to-moderate COVID-19 symptoms in India.
-
Glenmark completed the phase 3 clinical trial with Favipiravir (FabiFlu) in mild to moderate COVID-19 patients in India.
-
Glenmark allegedly conspired with pharmaceutical maker Apotex Corp and other generic drug companies to increase the prices of cholesterol medication pravastatin and other generic drugs, the department said.
-
Deferasirox is used to treat high levels of iron in the body caused by multiple blood transfusions.
-
According to the latest Enforcement Report by the US Food and Drug Administration (USFDA), Glenmark Pharmaceuticals Inc USA is recalling the product in various strengths which was manufactured at company's Goa manufacturing facility.
-
Glenmark said it will continue to pursue regulatory approval for Ryaltris and work closely with the FDA to determine the appropriate next steps
-
The product is a generic version of Sun Pharmaceutical Industries' Westcort Cream in the same strength, it added.
-
Axis Direct is bullish on Glenmark has recommended buy rating on the stock with a target price of Rs 840 in its research report dated August 02, 2017.
-
Titan's EBIT from the jewellery business is ten times the EBIT from watches plus eyewear business put together, said Udayan Mukherjee.
-
The profits were impacted due to an Rs 81 crore exceptional item, high expenses and decline in sales across Europe, Latin America, and other markets. The expenses shot up 13.6 percent to Rs 2152 crore on sequential basis.
-
Axis Direct is bullish on Glenmark Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1100 in its research report dated March 24, 2017.
-
Sudarshan Sukhani of s2analytics.com suggests selling Tata Motors and Glenmark Pharma and advises buying Colgate Palmolive.
-
Glenmark's medicines, Zita and Zita-Met, cost 30 percent less than MSD's Januvia and Janumet, which is due to the customs duty paid by the US firm, the High Court had said and added that "no allegation has been made that MSD on Wednesday sells its drugs at a relatively high price that hinders access to the drug".
